Understanding of BRCA VUS genetic results by breast cancer specialists

[1]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[2]  A. Howell,et al.  The Angelina Jolie effect: how high celebrity profile can have a major impact on provision of cancer related services , 2014, Breast Cancer Research.

[3]  S. Verma,et al.  The impact of Angelina Jolie's (AJ) story on genetic referral and testing at an academic cancer centre. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Julie O. Culver,et al.  Variants of uncertain significance in BRCA testing: evaluation of surgical decisions, risk perception, and cancer distress , 2013, Clinical genetics.

[5]  F. Couch,et al.  BRCA1/2 sequence variants of uncertain significance: a primer for providers to assist in discussions and in medical management. , 2013, The oncologist.

[6]  A. Kiss,et al.  Variants of unknown significance in BRCA testing: impact on risk perception, worry, prevention and counseling. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  A. Devereau,et al.  Practice Guidelines for the Evaluation of Pathogenicity and the Reporting of Sequence Variants in Clinical Molecular Genetics . , 2013 .

[8]  F. Couch,et al.  BRCA1 R1699Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer risk , 2012, Journal of Medical Genetics.

[9]  C. Stanislaw,et al.  Adverse Events in Cancer Genetic Testing: Medical, Ethical, Legal, and Financial Implications , 2012, Cancer journal.

[10]  Sue Healey,et al.  ENIGMA—Evidence‐based network for the interpretation of germline mutant alleles: An international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes , 2012, Human mutation.

[11]  Fergus J Couch,et al.  A review of a multifactorial probability‐based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS) , 2012, Human mutation.

[12]  Gail P Jarvik,et al.  Follow-up of carriers of BRCA1 and BRCA2 variants of unknown significance: Variant reclassification and surgical decisions , 2011, Genetics in Medicine.

[13]  G. Hortobagyi,et al.  Cancer Risk Management Decisions of Women with BRCA1 or BRCA2 Variants of Uncertain Significance , 2011, The breast journal.

[14]  Tao Wang,et al.  Genetic testing and cancer risk management recommendations by physicians for at-risk relatives , 2011, Genetics in Medicine.

[15]  P. Radice,et al.  Unclassified variants in BRCA genes: guidelines for interpretation. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  K. Brierley,et al.  Errors in delivery of cancer genetics services: implications for practice. , 2010, Connecticut medicine.

[17]  S. Verhoef,et al.  BRCA testing of breast cancer patients: medical specialists' referral patterns, knowledge and attitudes to genetic testing. , 2010, European journal of cancer care.

[18]  N. Keating,et al.  Physicians' experiences with BRCA1/2 testing in community settings. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  A. Spurdle,et al.  Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results , 2008, Human mutation.

[20]  W. Otten,et al.  The counsellees' view of an unclassified variant in BRCA1/2: recall, interpretation, and impact on life , 2008, Psycho-oncology.

[21]  Fergus J Couch,et al.  A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. , 2007, American journal of human genetics.

[22]  D. Bishop,et al.  Breast and Ovarian Cancer Incidence in BRCA I -Mutation Carriers , 2007 .

[23]  R. Eeles,et al.  Too much, too soon? Patients and health professionals' views concerning the impact of genetic testing at the time of breast cancer diagnosis in women under the age of 40. , 2005, European journal of cancer care.

[24]  P. Devilee,et al.  Unclassified variants in disease-causing genes: nonuniformity of genetic testing and counselling, a proposal for guidelines , 2005, European Journal of Human Genetics.

[25]  N. Holtzman,et al.  Does knowledge about the genetics of breast cancer differ between nongeneticist physicians who do or do not discuss or order BRCA testing , 2003 .

[26]  D. Easton,et al.  Cancer incidence in BRCA1 mutation carriers , 2003 .

[27]  N. Holtzman,et al.  Does knowledge about the genetics of breast cancer differ between nongeneticist physicians who do or do not discuss or order BRCA testing? , 2003, Genetics in Medicine.

[28]  K. Huelsman,et al.  Clinical interpretation and recommendations for patients with a variant of uncertain significance in BRCA1 or BRCA2: a survey of genetic counseling practice. , 2002, Genetic testing.

[29]  M. Escher,et al.  Primary care physicians' knowledge and attitudes towards genetic testing for breast-ovarian cancer predisposition. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  D. Easton,et al.  Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. , 1995, American journal of human genetics.

[31]  M. Skolnick,et al.  BRCA1 mutations in primary breast and ovarian carcinomas. , 1994, Science.

[32]  Steven E. Bayer,et al.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.